A two stage, open-label, phase II trial assessing the efficacy of a single oral agent AZD4547 in malignant mesothelioma.
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs AZD 4547 (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 15 Feb 2017 Status changed from not yet recruiting to recruiting.
- 05 Jul 2016 New trial record